With 1.65 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.7 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $57.30 whereas the lowest price it dropped to was $56.50. The 52-week range on INCY shows that it touched its highest point at $76.04 and its lowest point at $50.27 during that stretch. It currently has a 1-year price target of $74.59. Beta for the stock currently stands at 0.65.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of INCY was down-trending over the past week, with a drop of -1.92%, but this was down by -6.36% over a month. Three-month performance dropped to -8.68% while six-month performance fell -3.64%. The stock lost -19.33% in the past year, while it has lost -9.03% so far this year. A look at the trailing 12-month EPS for INCY yields 2.64 with Next year EPS estimates of 5.35. For the next quarter, that number is 0.86. This implies an EPS growth rate of 25.25% for this year and 21.20% for next year. EPS is expected to grow by 22.50% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 38.99%.
Float and Shares Shorts:
At present, 224.29 million INCY shares are outstanding with a float of 221.85 million shares on hand for trading. On Feb 29, 2024, short shares totaled 7.77 million, which was 3.46% higher than short shares on Jan 31, 2024. In addition to ONCY as the firm’s Oncolytics Biotech Inc., INCR serves as its Intercure Ltd.
Institutional Ownership:
Through their ownership of 100.15% of INCY’s outstanding shares, institutional investors have majority control over the company.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for INCY since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.
Dividends & Yield:
In terms of dividends, INCY has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and INCY currently yields $0.00. In the past year, INCY’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, INCY has a current buyback yield of $–. This was $– for the TTM, and it was $– for the past five years.
